Exploring Clinical Remission in Moderate Asthma - Perspectives from Asia, the Middle East, and South America.
Agreement
Delphi
Exacerbations
Lung function
Moderate asthma
Oral corticosteroids
Remission
Surveys
Symptoms
Journal
Pulmonary therapy
ISSN: 2364-1746
Titre abrégé: Pulm Ther
Pays: United States
ID NLM: 101687144
Informations de publication
Date de publication:
04 Jun 2024
04 Jun 2024
Historique:
received:
23
04
2024
accepted:
24
05
2024
medline:
4
6
2024
pubmed:
4
6
2024
entrez:
4
6
2024
Statut:
aheadofprint
Résumé
Clinical remission is a relatively new concept in asthma but recent research initiatives suggest it could be an ambitious and achievable therapeutic target for patients with asthma. In this modified Delphi study (comprising two online surveys, completed either side of a virtual scientific workshop), the opinions of a panel of respiratory physicians were evaluated to summarize perspective statements on key therapeutic outcomes and criteria for on-treatment clinical remission in patients with moderate asthma. An agreement threshold was pre-defined as agreement by ≥ 75% of participants. Surveys 1 and 2 were completed by 20 and 18 participants, respectively. Most participants (95%) agreed with the concept of clinical remission in moderate asthma and that this should be a desirable treatment goal (90%). Based on a composite measure of 4-6 desirable therapeutic outcomes, current understanding of clinical remission was considered as 12 months with no exacerbations, no oral corticosteroids, no daytime or night-time asthma symptoms (Asthma Control Test score ≥ 20 or Asthma Control Questionnaire score ≤ 0.75), stable lung function, and no treatment-related adverse events. No agreement was reached on the role of relievers in defining therapeutic outcomes or on the wider use of biomarkers and airway hyperresponsiveness for defining asthma remission in clinical practice. In line with recent consensus statements from the United States and Europe, there was a high level of agreement on the elements of clinical remission among a panel of respiratory physicians from Asia, the Middle East, and South America. Extension of the concept of clinical remission to patients with moderate asthma was considered aligned with the potential of clinical remission as a goal of therapy.
Identifiants
pubmed: 38833146
doi: 10.1007/s41030-024-00262-2
pii: 10.1007/s41030-024-00262-2
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
NICE guideline. Rheumatoid arthritis in adults: management; 2020. Available at: www.nice.org.uk/guidance/ng100 . Last Accessed 2 Nov 2023.
Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73:924–39.
doi: 10.1002/acr.24596
pubmed: 34101387
Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
doi: 10.1136/ard-2022-223356
pubmed: 36357155
Vuitton L, Peyrin-Biroulet L, Colombel JF, et al. Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. Aliment Pharmacol Ther. 2017;45:801–13.
doi: 10.1111/apt.13948
pubmed: 28112419
van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017;76:554–61.
doi: 10.1136/annrheumdis-2016-209519
pubmed: 27884822
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023. Available from: https://ginasthma.org/gina-reports/ . Accessed 29 Nov 2023.
Bateman ED, Boushey HA, Bousquet J, GOAL Investigators Group, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med. 2004;170:836–44.
doi: 10.1164/rccm.200401-033OC
pubmed: 15256389
Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev. 2010. https://doi.org/10.1002/14651858.CD005533.pub2 .
doi: 10.1002/14651858.CD005533.pub2
pubmed: 21154378
Aggarwal B, Shantakumar S, Hinds D, Mulgirigama A. Asia-Pacific survey of physicians on asthma and allergic rhinitis (ASPAIR): physician beliefs and practices about diagnosis, assessment, and treatment of coexistent disease. J Asthma Allergy. 2018;11:293–307.
doi: 10.2147/JAA.S180657
pubmed: 30588037
pmcid: 6294166
Chapman KR, Canonica GW, Lavoie KL, et al. Patients’ and physicians’ perspectives on the burden and management of asthma: results from the APPaRENT 2 study. Respir Med. 2022;201: 106948.
doi: 10.1016/j.rmed.2022.106948
pubmed: 36029695
Bårnes CB, Ulrik CS. Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respir Care. 2015;60:455–68.
doi: 10.4187/respcare.03200
pubmed: 25118311
Pavord I, Gardiner F, Heaney LG, et al. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study. Front Immunol. 2023;14:1150162.
doi: 10.3389/fimmu.2023.1150162
pubmed: 37122713
pmcid: 10131245
Thomas D, McDonald VM, Stevens S, et al. Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients. Allergy. 2024;79:384–92.
doi: 10.1111/all.15867
pubmed: 37632144
Sposato B, Bianchi F, Ricci A, Scalese M. Clinical asthma remission obtained with biologics in real life: Patients’ prevalence and characteristics. J Pers Med. 2023;13:1020.
doi: 10.3390/jpm13061020
pubmed: 37374008
pmcid: 10305708
Lugogo NL, Mohan A, Arbor A, et al. Are we ready for asthma remission as a clinical outcome? Chest. 2023;164:831–4.
doi: 10.1016/j.chest.2023.04.028
pubmed: 37805244
Menzies-Gow A, Bafadhel M, Busse WW, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145(3):757–65.
doi: 10.1016/j.jaci.2019.12.006
pubmed: 31866436
Lugogo N, Oppenheimer J, Crawford J, et al. Is asthma clinical remission achievable by inhaled therapy? A post-hoc analysis of single inhaler triple therapy with FF/UMEC/VI in the CAPTAIN trial. J Allergy Clin Immunol. 2024;153(supplement issue 2):AB266.
doi: 10.1016/j.jaci.2023.11.851
Canonica GW, Blasi F, Carpagnano GE, et al. Severe Asthma Network Italy definition of clinical remission in severe asthma: a Delphi consensus. J Allergy Clin Immunol Pract. 2023;S2213–2198(23):00816–24.
Blaiss M, Oppenheimer J, Corbett M, et al. Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment. Ann Allergy Asthma Immunol. 2023;131:782–5.
doi: 10.1016/j.anai.2023.08.609
pubmed: 37690606
Association BHBI. BHBIA legal and ethical guidelines for healthcare market research. Hertfordshire, UK: British Healthcare Business Intelligence Association 2024. https://www.bhbia.org.uk/guidelines-and-legislation/legal-and-ethical-guidelines . Accessed 26 April 2024.
European Pharmaceutical Market Research Association’s (EphMRA) code of conduct 2023. https://www.ephmra.org/code-conduct-aer . Accessed 26 April 2024.
Bousquet J, Winchester C, Papi A, et al. Global allergy and asthma European network (GA
doi: 10.1159/000329519
pubmed: 22056555
Harding G, Leidy NK, Meddis D, Kleinman L, Wagner S, O’Brien CD. Interpreting clinical trial results of patient-perceived onset of effect in asthma: methods and results of a Delphi panel. Curr Med Res Opin. 2009;25:1563–71.
doi: 10.1185/03007990902914403
pubmed: 19445651
Sheikh A, Major P, Holgate ST. Developing consensus on national respiratory research priorities: key findings from the UK respiratory research Collaborative’s e-Delphi exercise. Respir Med. 2008;102:1089–92.
doi: 10.1016/j.rmed.2008.03.006
pubmed: 18573646
Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs. 2000;32:1008–15.
doi: 10.1046/j.1365-2648.2000.t01-1-01567.x
pubmed: 11095242
Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS ONE. 2011;6: e20476.
doi: 10.1371/journal.pone.0020476
pubmed: 21694759
pmcid: 3111406
Slade SC, Dionne CE, Underwood M, Buchbinder R. Standardised method for reporting exercise programmes: protocol for a modified Delphi study. BMJ Open. 2014;4: e006682.
doi: 10.1136/bmjopen-2014-006682
pubmed: 25550297
pmcid: 4281530
Vogel C, Zwolinsky S, Griffiths C, Hobbs M, Henderson E, Wilkins E. A Delphi study to build consensus on the definition and use of big data in obesity research. Int J Obes (Lond). 2019;43:2573–86.
doi: 10.1038/s41366-018-0313-9
pubmed: 30655580
Domingo C, Garcia G, Gemicioglu B, et al. Consensus on mild asthma management: results of a modified Delphi study. J Asthma. 2023;60:145–57.
doi: 10.1080/02770903.2022.2034850
pubmed: 35099342
The British Thoracic Society. BTS/SIGN British guideline on the management of asthma, 2019. < https://www.brit-thoracic.org.uk/standards-of-care/guidelines/btssign-british-guideline-on-the-management-of-asthma/ >. Accessed 29 Nov 2023.
Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC), Cloutier MM, Baptist AP, Blake KV, et al. 2020 Focused updates to the asthma management guidelines: a report from the national asthma education and prevention program coordinating committee expert panel working group. J Allergy Clin Immunol. 2020;146(6):1217–70.
doi: 10.1016/j.jaci.2020.10.003
Charriot J, Gaga M, Suehs C, Bourdin A. Asthma rescue treatments, time to reboot. Eur Respir J. 2020;55:2000542.
doi: 10.1183/13993003.00542-2020
pubmed: 32300023
Volpe FM. Cause or consequence? Eur Respir J. 2022;59(6):2103107.
doi: 10.1183/13993003.03107-2021
pubmed: 35210318
Amirav I, Garcia G, Le BK, Barria P, Levy G, Aggarwal B, Fahrbach K, Martin A, Phansalkar A, Sriprasart T. SABAs as reliever medications in asthma management: evidence-based science. Adv Ther. 2023;40:2927–43.
doi: 10.1007/s12325-023-02543-9
pubmed: 37280414
pmcid: 10244083
Sriprasart T, Waterer G, Garcia G, Rubin A, Andrade MAL, Roguska A, Phansalkar A, Fulmali S, Martin A, Mittal L, Aggarwal B, Levy G. Safety of SABA monotherapy in asthma management: a systematic review and meta-analysis. Adv Ther. 2023;40:133–58.
doi: 10.1007/s12325-022-02356-2
pubmed: 36348141
Juniper EF. Assessing asthma quality of life: its role in clinical practice. Breathe. 2005;1:192–204.
doi: 10.1183/18106838.0103.192
Canonica GW, Spanevello A, de Llano LP, Domingo Ribas C, Blakey JD, Garcia G, Inoue H, Dalcolmo M, Yang D, Mokashi S, Kurne A, Butta AK. Is asthma control more than just an absence of symptoms? An expert consensus statement. Respir Med. 2022;202: 106942.
doi: 10.1016/j.rmed.2022.106942
pubmed: 36096072
Ward C, Pais M, Bish R, et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax. 2002;57:309–16.
doi: 10.1136/thorax.57.4.309
pubmed: 11923548
pmcid: 1746305
Lommatzsch M, Brusselle GG, Canonica GW, Jackson DJ, Nair P, Buhl R, Virchow JC. Disease-modifying anti-asthmatic drugs. Lancet. 2022;399:1664–8.
doi: 10.1016/S0140-6736(22)00331-2
pubmed: 35461560